Metrics to compare | RDG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 113.9x | −5.3x | −0.4x | |
PEG Ratio | - | 0.03 | 0.00 | |
Price/Book | 17.0x | 4.9x | 2.6x | |
Price / LTM Sales | 3.5x | 6.3x | 3.0x | |
Upside (Analyst Target) | - | 84.9% | 47.5% | |
Fair Value Upside | Unlock | 7.9% | 6.7% | Unlock |
Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries. In addition, the company offers genetic tests; and advisory services for genetic counseling and support for oncological genetic counseling centers. Further, it operates an online platform for genetic tests and genetic-oncological consultations. The company was incorporated in 2005 and is based in Szczecin, Poland. Read-Gene S.A. operates as a subsidiary of Gen-Pat-Med Sp. z o.o.